Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3159822 | 0.94 | LMNA (0.40) | LMNA | |
| SCHEMBL3162273 | 0.85 | LMNA (0.43) | LMNA | |
| SCHEMBL8896279 | 0.85 | SPHK1 (0.45) | LMNASPHK1CYP2D6GMNNPOLB | |
| SCHEMBL7191735 | 0.82 | LMNA (0.44) | LMNASPHK1CYP2D6GMNNPOLB | |
| SCHEMBL3157975 | 0.80 | LMNA (0.43) | LMNASPHK1CYP2D6GMNNPOLB | |
| SCHEMBL10635542 | 0.79 | SPHK1 (0.50) | LMNASPHK1CYP2D6GMNNPOLB | |
| SCHEMBL10632703 | 0.79 | SPHK1 (0.50) | LMNASPHK1CYP2D6GMNNPOLB | |
| SCHEMBL6664800 | 0.78 | LMNA (0.46) | LMNASPHK1CYP2D6GMNNPOLB | |
| SCHEMBL3163364 | 0.78 | LMNA (0.44) | LMNA | |
| SCHEMBL26211760 | 0.78 | SPHK1 (0.52) | LMNASPHK1CYP2D6GMNNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1219599-B1 | VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2 ALPHA-POSITION | TAKAYAMA HIROAKI (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20050113349-A1 | 2-Alpha vitamin D derivatives having substituents | HIROAKI TAKAYAMA (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-0947504-B1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6555699-B2 | Antitumor and antirheumatic agents, high binding affinity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6433200-B1 | ANTITUMOR AND ANTIRHEUMATIC AGENTS, HIGH BINDING AFINITY TO VITAMIN D RECEPTORS AND WEAK HYPERCALCEMIC ACTIVITY | CHUGEI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1219599-A1 | VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2 ALPHA-POSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-20020032340-A1 | 16-ene-vitamin D derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-1174424-A1 | 3-METHYLATED VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-01-23 | — | — | EP | disclosed |
| US-6326503-B1 | ANTITUMOR AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-1158297-A1 | METHOD FOR SCREENING COMPOUND HAVING AFFINITY FOR VITAMIN D RECEPTOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-6184398-B1 | ANTITUMOR AGENTS AND TREATMENT OF RHEUMATIC CONDITIONS; HIGH BINDING ABILITY TO VITAMIN D RECEPTORS AND WEAK HYPERCALCEMIC ACTIVITY; E.G.,1,3-DIHYDROXY-20-3-HYDROXY-3-METHYLBUTYLTHIO)-9,10-SECOPREGNA -5,7,10(19),16-TETRAENE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0947504-A1 | 16-ENE-VITAMIN D DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | VDR, CYP24A1, CYP2R1 | LMNA 1636/4885SPHK1 4029/4885CYP2D6 402/4885 |
| US-20050113349-A1 | 2-Alpha vitamin D derivatives having substituents | CYP24A1, CYP2R1, VDR | LMNA 944/4885SPHK1 2013/4885CYP2D6 377/4885 |
| US-20020032340-A1 | 16-ene-vitamin D derivatives | VDR, CYP2R1, CYP24A1 | LMNA 3455/4885SPHK1 3346/4885CYP2D6 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.